Determination of scutellarin in breviscapine preparations using quantitative proton nuclear magnetic resonance spectroscopy
The objective of the present study was to develop the selection criteria of proton signals for the determination of scutellarin using quantitative nuclear magnetic resonance (qNMR), which is the main bioactive compound in breviscapine preparations for the treatment of cerebrovascular disease. The methyl singlet signal of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt was selected as the internal standard for quantification. The molar concentration of scutellarin was determined by employing different proton signals. To obtain optimum proton signals for the quantification, different combinations of proton signals were investigated according to two selection criteria: the recovery rate of qNMR method and quantitative results compared with those obtained with ultra-performance liquid chromatography. As a result, the chemical shift of H-2′ and H-6′ at δ 7.88 was demonstrated as the most suitable signal with excellent linearity range, precision, and recovery for determining scutellarin in breviscapine preparations from different manufacturers, batch numbers, and dosage forms. Hierarchical cluster analysis was employed to evaluate the determination results. The results demonstrated that the selection criteria of proton signals established in this work were reliable for the qNMR study of scutellarin in breviscapine preparations. Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC.
Jiang, Z.; Yang, J.; Jiao, Y.; Li, W.; Chai, X.; Zhang, L.; Jiang, M.; and Wang, Y.
"Determination of scutellarin in breviscapine preparations using quantitative proton nuclear magnetic resonance spectroscopy,"
Journal of Food and Drug Analysis: Vol. 24
, Article 7.
Available at: https://doi.org/10.1016/j.jfda.2015.12.004
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.